^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    SOLIDaccuTest DNA

    Company:
    NGeneBio
    Type:
    CE Marked
    Related tests:
    Details
    Evidence

    News

    8ms
    NGenBio successfully supplies its first paid NGS analysis software to Romania (NGeneBio Press Release)
    "NGenBio...announced on the 26th that it has successfully launched its automated genome analysis software, NGeneAnalySys™ (NGAS), for the first time in Romania."
    Launch
    |
    BRCAaccuTest PLUS • HEMEaccuTest™ • SOLIDaccuTest DNA
    1year
    Germline mutations in patients with metastatic prostate cancer: A prospective cohort study in South Korea (KCSG GU20-19). (ASCO-GU 2024)
    The prevalence of pathogenic germline mutations among unselected Korean patients with metastatic prostate cancer was 12.0 %. Germline mutation prevalence in this cohort was comparable to previous reported results. This study provides the framework for the development of preventive and treatment strategies based on hereditary genetic factors for prostate cancer in the Korean population.P, pathogenic; LP, likely pathogenic.
    Clinical • BRCA Biomarker • Metastases
    |
    BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • SLFN11 (Schlafen Family Member 11) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • MRE11A (MRE11 homolog, double strand break repair nuclease) • FANCD2 (FA Complementation Group D2)
    |
    BRCA2 mutation • ATM mutation • FANCA mutation • BLM mutation
    |
    SOLIDaccuTest DNA